280 related articles for article (PubMed ID: 32612110)
21. Identification of integrative molecular and clinical profiles of Fibrinogen-like protein 2 in gliomas using 1323 samples.
Song Z; Wang Y; Du Y; Zhang Z; Yuan Y
Int Immunopharmacol; 2020 Nov; 88():106894. PubMed ID: 32858440
[TBL] [Abstract][Full Text] [Related]
22. Genetic and clinical characterization of B7-H3 (CD276) expression and epigenetic regulation in diffuse brain glioma.
Wang Z; Wang Z; Zhang C; Liu X; Li G; Liu S; Sun L; Liang J; Hu H; Liu Y; Zhang W; Jiang T
Cancer Sci; 2018 Sep; 109(9):2697-2705. PubMed ID: 30027617
[TBL] [Abstract][Full Text] [Related]
23. Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma.
Wang Z; Zhang C; Liu X; Wang Z; Sun L; Li G; Liang J; Hu H; Liu Y; Zhang W; Jiang T
Oncoimmunology; 2016; 5(11):e1196310. PubMed ID: 27999734
[No Abstract] [Full Text] [Related]
24. CD96 as a Potential Immune Regulator in Cancers.
Feng S; Isayev O; Werner J; Bazhin AV
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674817
[TBL] [Abstract][Full Text] [Related]
25. Molecular and clinical characterization of CD163 expression via large-scale analysis in glioma.
Liu S; Zhang C; Maimela NR; Yang L; Zhang Z; Ping Y; Huang L; Zhang Y
Oncoimmunology; 2019; 8(7):1601478. PubMed ID: 31143523
[TBL] [Abstract][Full Text] [Related]
26. An Immune-Related Signature for Predicting the Prognosis of Lower-Grade Gliomas.
Zhang H; Li X; Li Y; Chen B; Zong Z; Shen L
Front Immunol; 2020; 11():603341. PubMed ID: 33363544
[TBL] [Abstract][Full Text] [Related]
27. Transcriptome profile and clinical characterization of ICOS expression in gliomas.
Wang J; Shi F; Shan A
Front Oncol; 2022; 12():946967. PubMed ID: 36276141
[TBL] [Abstract][Full Text] [Related]
28. Clinical Value of TXNDC12 Combined With IDH and 1p19q as Biomarkers for Prognosis of Glioma.
Wang X; Yang Q; Liu N; Bian Q; Gao M; Hou X
Pathol Oncol Res; 2021; 27():1609825. PubMed ID: 34629960
[No Abstract] [Full Text] [Related]
29. A comprehensive bioinformatic analysis of cyclin-dependent kinase 2 (CDK2) in glioma.
Liu H; Weng J
Gene; 2022 May; 822():146325. PubMed ID: 35183683
[TBL] [Abstract][Full Text] [Related]
30. Identification of immunologic subtype and prognosis of GBM based on TNFSF14 and immune checkpoint gene expression profiling.
Long S; Li M; Liu J; Yang Y; Li G
Aging (Albany NY); 2020 Apr; 12(8):7112-7128. PubMed ID: 32310827
[TBL] [Abstract][Full Text] [Related]
31. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
[TBL] [Abstract][Full Text] [Related]
32. PDIA3 correlates with clinical malignant features and immune signature in human gliomas.
Zhang H; Zhou Y; Cheng Q; Dai Z; Wang Z; Liu F; Fan F; Cui B; Cao H
Aging (Albany NY); 2020 Aug; 12(15):15392-15413. PubMed ID: 32687065
[TBL] [Abstract][Full Text] [Related]
33. Identification of a five B cell-associated gene prognostic and predictive signature for advanced glioma patients harboring immunosuppressive subtype preference.
Zhang C; Li J; Wang H; Song SW
Oncotarget; 2016 Nov; 7(45):73971-73983. PubMed ID: 27738332
[TBL] [Abstract][Full Text] [Related]
34. Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy.
Blake SJ; Dougall WC; Miles JJ; Teng MW; Smyth MJ
Clin Cancer Res; 2016 Nov; 22(21):5183-5188. PubMed ID: 27620276
[TBL] [Abstract][Full Text] [Related]
35. Molecular and clinical characterization of TMEM71 expression at the transcriptional level in glioma.
Wang KY; Huang RY; Tong XZ; Zhang KN; Liu YW; Zeng F; Hu HM; Jiang T
CNS Neurosci Ther; 2019 Sep; 25(9):965-975. PubMed ID: 31180187
[TBL] [Abstract][Full Text] [Related]
36. Immune Checkpoint-Associated Locations of Diffuse Gliomas Comparing Pediatric With Adult Patients Based on Voxel-Wise Analysis.
Zhang L; Zhang B; Dou Z; Wu J; Iranmanesh Y; Jiang B; Sun C; Zhang J
Front Immunol; 2021; 12():582594. PubMed ID: 33815356
[No Abstract] [Full Text] [Related]
37. Clinical characterization and immunosuppressive regulation of CD161 (KLRB1) in glioma through 916 samples.
Di W; Fan W; Wu F; Shi Z; Wang Z; Yu M; Zhai Y; Chang Y; Pan C; Li G; Kahlert UD; Zhang W
Cancer Sci; 2022 Feb; 113(2):756-769. PubMed ID: 34881489
[TBL] [Abstract][Full Text] [Related]
38. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
[TBL] [Abstract][Full Text] [Related]
39. Immune Cytolytic Activity Is Associated With Genetic and Clinical Properties of Glioma.
Wang ZL; Wang Z; Li GZ; Wang QW; Bao ZS; Zhang CB; Jiang T
Front Immunol; 2019; 10():1756. PubMed ID: 31428092
[No Abstract] [Full Text] [Related]
40. Six Immune Associated Genes Construct Prognostic Model Evaluate Low-Grade Glioma.
Tan YQ; Li YT; Yan TF; Xu Y; Liu BH; Yang JA; Yang X; Chen QX; Zhang HB
Front Immunol; 2020; 11():606164. PubMed ID: 33408717
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]